Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT ID: NCT00085345

Last Updated: 2013-07-10

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as melphalan, arsenic trioxide, and ascorbic acid, work in different ways to stop cancer cells from dividing so they stop growing or die. Arsenic trioxide and ascorbic acid may also help melphalan kill more cancer cells by making them more sensitive to the drugs.

PURPOSE: This phase II trial is studying how well giving melphalan together with arsenic trioxide and ascorbic acid works in treating patients with relapsed or refractory multiple myeloma.

Detailed Description

OBJECTIVES:

Primary

• Determine the time to progression in patients with relapsed or refractory multiple myeloma (MM) treated with melphalan, arsenic trioxide, and ascorbic acid.
• Determine the response rate (combined complete response, partial response, and minimal response) in patients treated with this regimen.
• Determine the safety and tolerability of this regimen in these patients.

Secondary

• Determine the time to response and overall survival of patients treated with this regimen.
• Determine the effects of this regimen on renal failure associated with MM in these patients.

OUTLINE: This is an open-label, non-randomized, multicenter study.

Patients receive oral melphalan once daily on days 1-4 of week 1 and arsenic trioxide (ATO) IV over 1-2 hours and ascorbic acid IV over 15 minutes on days 1-4 of week 1 and then twice weekly during weeks 2-5. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression any time after course 1 also receive oral prednisone once daily on days 1-4 and 22-25 of each course. Patients achieving a complete response after 6 courses of therapy undergo bone marrow biopsy and receive no further therapy. Patients achieving stable disease or a partial response after 6 courses of therapy continue to receive ATO and ascorbic acid once weekly.

Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 65 patients will be accrued for this study.

Conditions

Stage II Multiple Myeloma; Stage III Multiple Myeloma; Refractory Plasma Cell Neoplasm

Study Design

• Primary Study Purpose: TREATMENT

Interventions

arsenic trioxide

Intervention Type: DRUG

ascorbic acid

Intervention Type: DRUG

melphalan

Intervention Type: DRUG

chemosensitization/potentiation

Intervention Type: PROCEDURE

chemotherapy

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of multiple myeloma meeting at least 1 of the following criteria:
• Relapsed disease after a response to standard first-line chemotherapy (e.g., vincristine, doxorubicin, and dexamethasone [VAD] OR melphalan and prednisone) or first-line high-dose chemotherapy
• Refractory disease (failed to achieve at least stable disease) to most recent chemotherapy with or without systemic corticosteroids
• Measurable disease, defined as a monoclonal immunoglobulin spike on serum electrophoresis of ≥ 1 g/dL AND/OR urine monoclonal immunoglobulin spike of ≥ 200 mg/24 hours
• No non-secretory myeloma
• No plasma cell leukemia

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• Karnofsky 60-100%

Life expectancy

• More than 3 months

Hematopoietic

• Platelet count ≥ 50,000/mm^3 (30,000/mm^3 if bone marrow is extensively infiltrated)
• Hemoglobin ≥ 8.0 g/dL
• Absolute neutrophil count ≥ 1,000/mm^3
• Pancytopenia secondary to multiple myeloma or hypersplenism allowed

Hepatic

• AST and ALT ≤ 3 times upper limit of normal (ULN)
• Bilirubin ≤ 2 times ULN (unless clearly related to disease)
• No known active hepatitis B or C infection

Renal

• Calcium < 14 mg/dL

Cardiovascular

• No evidence of acute ischemia or new conduction system abnormality by electrocardiogram
• No myocardial infarction within the past 6 months
• No New York Heart Association class III or IV heart failure
• No poorly controlled hypertension
• No prolonged corrected QT interval (> 460 ms) with potassium > 4 mmol/L and magnesium ≥ 1.8 mmol/L

Other

• No active infection
• No POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
• No diabetes mellitus
• No other serious medical or psychiatric illness that would preclude study participation
• No known allergic reaction attributable to compounds of similar chemical or biological composition to study drugs
• No history of grand mal seizures
• HIV negative
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy

• More than 4 weeks since prior immunotherapy or antibody therapy

Chemotherapy

• See Disease Characteristics
• More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)

Endocrine therapy

• See Disease Characteristics
• No other concurrent corticosteroids

Radiotherapy

• More than 4 weeks since prior radiotherapy

Surgery

• More than 4 weeks since prior major surgery

Other

• No other concurrent investigational agents

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Oncotherapeutics

INDUSTRY

Sponsor Role: lead

Principal Investigators

James R. Berenson, MD

Role: STUDY_CHAIR

Oncotherapeutics

Locations

Palo Verde Hematology Oncology

Glendale, Arizona, United States

Comprehensive Blood and Cancer Center

Bakersfield, California, United States

Southbay Oncology / Hematology Medical Group

Campbell, California, United States

Fountain Valley, California, United States

Hematology-Oncology Medical Group of Fresno, Incorporated

Fresno, California, United States

Hematology Oncology Medical Group of Orange County, Incorporated

Orange, California, United States

Cancer Care Associates Medical Group - Redondo Beach

Redondo Beach, California, United States

Redwood Regional Oncology Center - Sotoyome

Santa Rosa, California, United States

Cancer Prevention and Treatment Center at Dominican and Watsonville Community Hospital

Soquel, California, United States

San Diego Cancer Center - Vista

Vista, California, United States

Oncotherapeutics

West Hollywood, California, United States

Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center

Miami Beach, Florida, United States

Atlanta Cancer Care - Roswell

Roswell, Georgia, United States

Tulane Cancer Center at Tulane University Hospital and Clinic

New Orleans, Louisiana, United States

Center for Cancer and Blood Disorders at Suburban Hospital

Bethesda, Maryland, United States

William Beaumont Hospital - Royal Oak Campus

Royal Oak, Michigan, United States

Hackensack University Medical Center Cancer Center

Hackensack, New Jersey, United States

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Utah Cancer Specialists - Administrative Office

Salt Lake City, Utah, United States

Countries

United States

Other Identifiers

CDR0000368637

Identifier Type: REGISTRY

Identifier Source: secondary_id

ONCOTHER-MAC001

Identifier Type: -

Identifier Source: org_study_id